Business

Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said that its eNOcare iNO platform is almost ready to launch and that clinical trials of its eNOfit wearable iNO device are expected to begin by the … [Read more...] about Inhaled NO developer Third Pole closes $25 million financing round

Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both dry powder and liquid inhalation formulations in collaboration with Lumen Bioscience, the University of Alabama at … [Read more...] about Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs

Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company's pipeline, which includes its PanFlu intranasal mAb vaccine against both influenza A and B. Leyden Labs previously announced a €40 million Series A financing in March 2021. In … [Read more...] about Leyden Labs raises $140 million for development of intranasal vaccines

According to Opiant Pharmaceuticals, the company's contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene nasal spray for the treatment of opioid overdose. In July 2021, Opiant announced positive results … [Read more...] about Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene

Aculys Pharma has acquired development and commercialization rights to Neurelis's Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and Vietnam. Aculys, which launched in 2021, describes itself as "a biopharmaceutical … [Read more...] about Aculys Pharma gets rights to Valtoco nasal spray in Japan, Australia, and other Asia-Pacific countries

Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make an upfront payment as well as future payments based on regulatory and sales milestones. Glenmark … [Read more...] about Lotus gets rights to market Ryaltris nasal spray in Singapore, Hong Kong, and Vietnam

According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding module (mCBM) nasal spray for the prevention of respiratory viruses. Pneumagen initiated a Phase 1 study of Neumifil in November 2021 and … [Read more...] about Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray